Marco Meglio

The phase 3 study will commence following the results of the phase 2b/3 AB10015 study, in which masitinib significantly slowed disease progression in combination with riluzole.

Treatment with in-hospital remote ischemic perconditioning did not reduce brain infarction volume growth and showed similar mortality rates for the intervention and control groups in the RESCUE-BRAIN study.

Cognitive change over time was similar in both the aspirin and placebo groups.

Full data from the ARCADE study of Ovid’s soticlestat is expected to be released in the first quarter of 2021.

Systemic blood pressure of

Study results suggest that unexplained seizures in older adults may also be a first sign of a neurodegenerative disease.

Researchers noted at least a 50% reduction from baseline in mean number of moderate to severe migraine days per month in 48% of the rimegepant group.

Data suggests that the longer the extubation time following mechanical thrombectomy, the higher the risk of unfavorable outcomes and pneumonia.

By the end of the open-label extension, 15-17% of patients showed clinically meaningful first response with eculizumab treatment.

Patients with spinal muscular atrophy maintained the ability to thrive and achieved motor milestones previously unseen in natural history studies.

In addition to no-charge testing, patients may have access to the Detect Muscular Dystrophy program, a counseling program designed to aid health decisions and follow-up care.

Nearly all patients in this cohort achieved a clinically meaningful >3-point increase during the study period, demonstrating a consistent response to the gene therapy.

No unexpected safety signals were reported in the post hoc analysis.

After meeting co-primary end points of pain freedom and freedom from the most bothersome symptom, the acute migraine agent has been cleared for a phase 3 trial by the FDA.

Eligible patients with Duchenne muscular dystrophy may receive the drug while it is under priority review by the FDA.

Patients with multiple sclerosis who reported cannabis use noted that it was helpful in relieving pain, as well as other symptoms, such as sleep, depression, anxiety, and/or stress.

The risk of relapse was higher with treatment of mycophenolate mofetil in patients with neuromyelitis optica spectrum disorder and other first-line immunosuppressants, compared to treatment with rituximab.

Eton Pharmaceuticals plans to submit a new drug application for ET-101 in the third quarter of 2020, anticipating its formulation to be the first approved oral topiramate solution.

A combination of different physical therapy interventions designed to improve fitness, motor function, and gait are all recommended when guiding clinical practice for patients with Huntington disease.

The ongoing phase 3 trial of the Biohaven drug is expected to be completed October 20, 2021.

Statistically significant associations between stress-related disorders were identified in those with Alzheimer disease, but not with Parkinson disease or amyotrophic lateral sclerosis.

Patients opted for nontriptan acute medications such as opioids and nonsteroidal anti-inflammatory drugs instead of staying on triptans at 12- and 24-month follow-ups.

Further results of the SPI2 trial will be presented at the upcoming American Academy of Neurology 2020 Annual Meeting in Toronto.

The label expansion now allows patients who require non-brain MRI monitoring to receive treatment with the stimulation device.

Despite the introduction of second-generation ASMs, drug tolerability has been relatively unchanged over the last 30 years.

The drug’s Prescription Drug User Fee Act date is set for October 20, 2020.

Compared with intensive care units or normal wards, stroke units were associated with reduced mortality in patients with intracranial hemorrhage.

Patients with relapsing multiple sclerosis showed declining scores on tests of cognitive processing speeds from baseline to 3-month follow-up post-relapse.

The chief executive officer of Clene Nanomedicine discussed CNM-Au8, their novel investigational drug that will be used in the world’s first platform trial of potential ALS treatments.

Both the 10- and 20-mg doses were associated with clinically relevant reductions in convulsive seizures with a favorable safety and tolerability profile.